Saturday 17 October 2026
Export WINT’s income statement to Excel — free account
Windtree Therapeutics, Inc.
WINT Healthcare Biotechnology
In the quarter to September 2025, EPS grew 99.5% and free cash flow grew 1.12%, each against the same quarter a year earlier.
0.00
0.00
NaN
Follow WINT
Windtree Therapeutics, Inc. (WINT) P/E ratio
Windtree Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 5.0× (December 2018) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2019 | 0.0× | — |
| Jun 2019 | 0.0× | — |
| Mar 2019 | 0.0× | — |
| Dec 2018 | 0.0× | — |
| 15 more quarters | Free account |
Against its own ten years
Low 0.0×
High 5.0×
Ten-year median
0.0×
Current reading's percentile
91
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| MTNB Matinas Biopharma Holdings, Inc. compare | n/m |
| VBIO Valion Bio, Inc. compare | n/m |
| KAPA Kairos Pharma, Ltd. compare | n/m |
| VRAX Virax Biolabs Group Limited compare | n/m |
| NTBLQ Notable Labs, Ltd. compare | n/m |
| ELAB PMGC Holdings Inc. compare | n/m |
| BPTSY Biophytis SA Sponsored ADR compare | n/m |
| BIORQ Biora Therapeutics, Inc. compare | n/m |
| WINT Windtree Therapeutics, Inc. | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)